BMC Psychiatry最新文献

{"title":"Trends in pharmacological prescriptions and polypharmacy for personality disorders: a 10-year cross-sectional analysis of naturalistic data.","authors":"Flavio Di Leone, Steinn Steingrimsson, Hanne Krage Carlsen, Sophie I Liljedahl, Peter Sand","doi":"10.1186/s12888-025-06716-4","DOIUrl":"10.1186/s12888-025-06716-4","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to examine trends in prescribing practices for individuals diagnosed with personality disorders (PD) over a 10-year period in a major metropolitan area in Sweden. Our aim was to assess the alignment of prescribing patterns with national clinical guidelines.</p><p><strong>Methods: </strong>A register analysis was conducted on 26,520 pharmacological prescriptions from patients' Electronic Health Records (EHRs), documented between January 2011 and December 2020. The study compared the annual proportion of prescriptions across various psychotropic medication classes over time between individuals diagnosed with PD alone and those diagnosed with PD and co-occurring clinical conditions. Additionally, polypharmacy (≥ 3 psychiatric medications) was investigated in both groups.</p><p><strong>Results: </strong>The proportion of individuals diagnosed with PD alone who received medication increased significantly over the study period. No significant changes were observed in polypharmacy, which remained prevalent in both groups. In the PD alone group, significant negative trends were observed in prescriptions for antidepressants, mood stabilizers, and benzodiazepine derivatives, while stimulant prescriptions rose significantly. In contrast, non-benzodiazepine sedatives and antipsychotics increased significantly in the group with co-occurring conditions.</p><p><strong>Conclusion: </strong>Our study indicates mixed adherence to Swedish national prescribing guidelines for PD. While there was alignment with recommendations, such as reduced benzodiazepine use, challenges remain in addressing polypharmacy and the prescribing of medications without clear indications, particularly in individuals without comorbidities. These findings emphasize the need for improved diagnostic accuracy, ongoing clinician education, and the integration of prescribing data with diagnostic and treatment records. Future research should explore prescribing practices across various clinical settings and assess the influence of psychopharmacological trends on prescribing, while also defining polypharmacy in the context of personality disorders to guide clinical practice.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"314"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of anxiety sensitivity on the observe facet of the five facet mindfulness questionnaire: differential item functioning in a clinical population.","authors":"Danielle Moskow Diamond, Joshua Curtiss, Joseph K Carpenter, Masaya Ito, Stefan G Hofmann","doi":"10.1186/s12888-025-06488-x","DOIUrl":"10.1186/s12888-025-06488-x","url":null,"abstract":"<p><strong>Background: </strong>Many individuals who engage in mindfulness experience decreased anxiety. Yet some individuals, particularly those with panic disorder (PD) or elevated anxiety sensitivity (AS), note heightened anxiety when observing particular sensations. The Five Facet Mindfulness Questionnaire (FFMQ) is one of the most widely utilized mindfulness questionnaires. However, its Observe facet has shown variability in the literature. This study explored a transdiagnostic approach to determine whether specific aspects of the Observe facet of the FFMQ differ in individuals with elevated anxiety sensitivity (AS).</p><p><strong>Methods: </strong>We examined a clinical sample of 1521 Japanese individuals who completed the FFMQ and Anxiety Sensitivity Index 3 (ASI-3). A multiple indicator multiple cause (MIMIC) model approach was adopted utilizing latent variables to examine differential item functioning (DIF) of the Observe facet of the FFMQ, based on PD and/or AS diagnosis. This process was repeated to examine the relationship between the Anxiety Sensitivity Index-3 (ASI-3) subscales and particular items of the Observe facet.</p><p><strong>Results: </strong>The measurement model revealed good acceptability of a one-factor solution of the Observe facet (χ² (20) = 208.73, p < 0.001). PD significantly predicted Observe (B = 0.09, R² = 0.06, p = 0.008) and AS significantly predicted Observe (B = 0.02, R² = 0.18, p < 0.001). Increased AS was associated with greater scores on observing internal items and lower scores on observing external items. When PD and AS were analyzed simultaneously, only AS remained significant. The cognitive subscale showed the same pattern of results as the total ASI-3 subscale.</p><p><strong>Conclusions: </strong>The findings of this study reveal that AS, particularly cognitive AS, may modulate the mindfulness experience. The study reveals the importance of understanding where an individual observes and its results may be beneficial for tailoring mindfulness interventions for individuals.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"312"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The trajectory of depressive symptoms and the association with quality of life and suicidal ideation in patients with major depressive disorder.","authors":"Wenjian Lai, Yuhua Liao, Huimin Zhang, Hao Zhao, Yanzi Li, Ruiying Chen, Guangduoji Shi, Yifen Liu, Jiejing Hao, Zehui Li, Wanxin Wang, Roger S McIntyre, Ciyong Lu, Xue Han","doi":"10.1186/s12888-025-06743-1","DOIUrl":"10.1186/s12888-025-06743-1","url":null,"abstract":"<p><strong>Background: </strong>Major depressive disorder (MDD) is the most prevalent mental health disorder globally. However, the association between depressive symptom trajectories in the early period and subsequent mental health outcomes remains not fully elucidated. This study aimed to delineate the depressive symptom trajectories during the initial phase of treatment, identify baseline characteristics associated with these trajectories, and explore the association of trajectories with subsequent quality of life and suicidal ideation.</p><p><strong>Methods: </strong>Participants were from the Depression Cohort in China. The diagnosis of MDD was assessed using the Mini-International Neuropsychiatric Interview (M.I.N.I.). Information on depressive symptom severity, quality of life, suicidal ideation and other demographics were collected. Latent class trajectory modeling was used to identify distinct classes of depressive symptom trajectories.</p><p><strong>Results: </strong>A total of 566 patients with MDD were included, and we identified 3 categories with differential trajectories characterized by improving class (66.7%), moderate decreasing class (27.7%), and persistent high class (5.6%). Compared to the improving class, severer anxiety and depressive symptoms at baseline increased the odds of belonging to the moderate decreasing class and persistent high class. Both moderate decreasing class and persistent high class were associated with increased risks of subsequent diminished quality of life. Additionally, only persistent high class was associated with a higher risk of subsequent suicidal ideation.</p><p><strong>Conclusion: </strong>Severe baseline anxiety and depressive symptoms identify a subpopulation of persons living with MDD who evince a greater likelihood of symptom worsening over time as well as greater decrements in quality of life and worsening measures of suicidality.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"310"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.","authors":"Hazem E Mohammed, Menna A Gomaa, Youssef Magdy Khalifa, Ahmed Ayman Shawky","doi":"10.1186/s12888-025-06696-5","DOIUrl":"10.1186/s12888-025-06696-5","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, a novel combination of xanomeline and trospium, offers potential therapeutic benefits for schizophrenia treatment by targeting muscarinic receptors and avoiding dopamine receptor blockade. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of KarXT.</p><p><strong>Methods: </strong>PubMed, Scopus, Web of Science, and Cochrane databases were systematically searched for relevant randomized controlled trials (RCTs) up to October 2024. Studies involving adult patients with schizophrenia treated with KarXT were included. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used to assess evidence quality, and the risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool.</p><p><strong>Results: </strong>Four studies with 690 participants were included. KarXT significantly reduced Positive and Negative Syndrome Scale (PANSS) total scores compared to placebo (mean difference (MD): -13.77, 95% confidence interval (CI) [-22.33 to -5.20], P-value = 0.002), with significant improvements in positive and negative subscale scores. It significantly increased the incidence of achieving ≥ 30% PANSS score reduction (risk ratio: 2.15, 95% CI [1.64 to 2.84], P < 0.00001). Moreover, KarXT demonstrated a favorable safety profile, with side effects such as nausea and constipation being mild and transient. Notably, it was not significantly associated with weight gain or extrapyramidal symptoms, which are common with traditional antipsychotics.</p><p><strong>Conclusions: </strong>KarXT's distinct mechanism and tolerability highlight its potential to address unmet needs in schizophrenia treatment. Future studies should explore its long-term efficacy, delayed adverse effects, and comparative effectiveness against existing therapies.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"309"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory burden index is correlated with increased depression: a population-based study.","authors":"Xiangzhi Shao, Zuopu Xie, Lielie Zhu","doi":"10.1186/s12888-025-06730-6","DOIUrl":"10.1186/s12888-025-06730-6","url":null,"abstract":"<p><strong>Background: </strong>Depression is intricately correlated with systemic inflammatory responses. The Inflammatory Burden Index (IBI) has recently been introduced as a comprehensive metric for evaluating systemic inflammation. This study aims to explore the correlation between IBI and depression in the general population.</p><p><strong>Methods: </strong>This cross-sectional study was designed to analyze the data from National Health and Nutrition Examination Survey (NHANES) during the period from 1999 to 2018. IBI was formulated as C-reactive protein×neutrophils/lymphocytes. The correlation between the prevalence of depression and IBI was explored through multivariate logistic regression analyses, as well as subgroup, interaction, restricted cubic spline (RCS) and sensitivity analyses.</p><p><strong>Results: </strong>A total of 14,557 subjects were included in this study, of whom, 1231 (8.5%) had depression. According to multivariate logistic regression and RCS analyses, a significantly linearly positive correlation was observed between IBI and depression [odds ratio (OR) = 1.03, 95% confidence intervals (CI): 1.01, 1.05, P = 0.007]. Subjects in the third tertile of IBI exhibited a significantly higher prevalence of depression, with 40.0% affected, compared to those in the first tertile (P < 0.001). This correlation was consistently observed across all subgroups through stratified analysis (all interaction P > 0.05). After sensitivity analyses excluding participants with upper and lower 2.5% of IBI, the correlation between IBI and depression remained stable (OR = 1.08; 95%CI, 1.01, 1.15, P < 0.001).</p><p><strong>Conclusion: </strong>These findings in this study indicate a positive correlation between IBI and depression in American adults. Further large-scale prospective studies are still needed to analyze the role of IBI in depression.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"306"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of lithium prescription in bipolar disorders in Nigeria.","authors":"Frances Nkechi Adiukwu, Mumeen Olaitan Salihu, Nafisatu Hayatudeen, Yesiru Adeyemi Kareem, Benjamin Olamide Adegoke, Ijeoma Chinanuekperem Charles-Ugwuagbo, Emmanuel Effiong Uwah, Ismail Olaiitan Adesina, Abba Mohammed Ibrahim, Muhammad Abba Fugu","doi":"10.1186/s12888-025-06736-0","DOIUrl":"10.1186/s12888-025-06736-0","url":null,"abstract":"<p><strong>Background: </strong>Lithium prescription rates have witnessed a significant downward trend over the years in different continents despite evidence of its clinical efficacy in the acute and long-term maintenance treatment of Bipolar Disorder (BD). Nigeria has a paucity of data on lithium use in BD management. Hence, we aim to investigate the lithium prescription rate and factors influencing its use among Nigerian psychiatrists and trainee psychiatrists.</p><p><strong>Methods: </strong>A cross-sectional survey involving 203 respondents working in different accredited psychiatric training facilities in Nigeria was conducted between April and May 2024 using a predesigned online Google form. Information relating to lithium use in managing the different phases of BD and factors influencing its use were assessed.</p><p><strong>Results: </strong>The mean age of the respondents was 37.98 (± 6.85) years. The lithium prescription rate is low (10.89%). There is a significant association between the respondents' awareness of clinical practice guidelines (CPG) and good adherence to CPG (p = 0.003), but this did not significantly influence lithium prescription among them. Older years of practice influence prescribing lithium (p = < 0.001). Monitoring and availability of lithium constituted significant concerns for lithium use, among other factors (p = 0.032).</p><p><strong>Conclusion: </strong>The study revealed a low lithium prescription rate among Nigerian psychiatrists and trainee psychiatrists compared to international studies. There is a need for concerted efforts towards addressing the identified factors. A review of the existing local CPG in line with the best evidence is warranted for improved clinical outcomes.</p><p><strong>Ethics registration: </strong>The study was approved by the Hospital Research and Ethical Committee (HREC) of the University of Port Harcourt Teaching Hospital (UPTH) with approval protocol number (UPTH/ADM/90/S.11/VOL.XI/1688).</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"304"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired emotional response inhibition among adolescents with bipolar depression: evidence from event-related potentials and behavioral performance.","authors":"Fangfang Chen, Cheng Chen, Mingfei Wu, Bingqing Luo, Han Cai, Fengqiong Yu, Lianzi Wang","doi":"10.1186/s12888-025-06748-w","DOIUrl":"10.1186/s12888-025-06748-w","url":null,"abstract":"<p><strong>Background: </strong>Impaired inhibition of inappropriate responses in the emotional context is a core feature in patients with bipolar disorder. However, there has been little research exploring the underlying mechanism of impaired response inhibition for emotional stimuli in adolescents with bipolar depression. To explore this issue, we employed event-related potentials (ERPs) to investigate the underlying neuroelectrophysiological mechanisms of inhibition of inappropriate emotional stimuli in adolescents with bipolar depression.</p><p><strong>Methods: </strong>Twenty-five adolescents with bipolar depression and nineteen healthy controls completed an emotional Go/No-Go task during electroencephalography recording. Reaction time (RT), reaction time variability (RTV), discriminability, and response bias were measured as behavioral performance indicators. ERP components, theta-band oscillation and inter-trial coherence (ITC) were compared between the two groups.</p><p><strong>Results: </strong>Behavioral performance analysis found that adolescents with bipolar depression showed smaller d' values, and larger RT and RTV, than healthy controls. Nogo-P3 amplitude was decreased in adolescents with bipolar depression in comparison with healthy controls. Theta-band oscillation and ITC for emotional stimuli were also reduced in adolescents with bipolar depression. Pearson correlation analysis showed there was a negative correlation between the Nogo-P3 amplitude induced by negative trials and RTV in adolescents with bipolar depression.</p><p><strong>Conclusion: </strong>Our findings suggest that adolescents with bipolar depression exhibit abnormal response inhibition in the emotional context. Impaired attentional function and discrimination of emotional information are related to the failure of behavioral inhibition in negative emotional contexts, and attenuated P3 amplitude and theta-band oscillation could be an electrophysiological indicator for this impairment.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"303"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"German version of the specific phobia of vomiting inventory (SPOVI): psychometric properties and correlates in a clinical and non-clinical sample.","authors":"Severin Hennemann, Antonia Weirich, Adrian Meule, Anne-Kathrin Bräscher, Michael Witthöft","doi":"10.1186/s12888-025-06744-0","DOIUrl":"10.1186/s12888-025-06744-0","url":null,"abstract":"<p><strong>Background: </strong>The Specific Phobia of Vomiting Inventory (SPOVI) is a 14-item instrument measuring behavioral avoidance and threat monitoring associated with emetophobia. The current study aimed to provide a German translation of the SPOVI and examine its psychometric properties and correlates.</p><p><strong>Methods: </strong>N = 441 adults from the general population and N = 465 outpatients with mental disorders completed the SPOVI and other self-report measures. Factor structure, reliability, convergent, and discriminant validity, as well as clinical utility, were investigated.</p><p><strong>Results: </strong>The German version of the SPOVI had a one-factor structure and high internal consistency in both samples (ωs > 0.90). Large correlations (rs > 0.50) with questionnaires assessing phobic anxiety, general anxiety, illness-related anxiety, and disgust sensitivity supported convergent validity, while relatively low correlations with questionnaires assessing depression, eating disorders or paranoid ideation supported discriminant validity. Among outpatients, those with a specific phobia diagnosis had the highest SPOVI scores.</p><p><strong>Conclusion: </strong>The German translation of the SPOVI has sound psychometric properties and is a potentially practical clinical screening instrument for emetophobia. PRE-REGISTRATION: https://aspredicted.org/5y6zb.pdf .</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"305"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormalities in cognitive-related functional connectivity can be used to identify patients with schizophrenia and individuals in clinical high-risk.","authors":"Yangpan Ou, Zhaobin Chen, Ying Wang, Huabing Li, Feng Liu, Ping Li, Dongsheng Lv, Yong Liu, Bing Lang, Jingping Zhao, Wenbin Guo","doi":"10.1186/s12888-025-06747-x","DOIUrl":"10.1186/s12888-025-06747-x","url":null,"abstract":"<p><strong>Background: </strong>Clinical high-risk (CHR) refers to prodromal phase before schizophrenia onset, characterized by attenuated psychotic symptoms and functional decline. They exhibit similar but milder cognitive impairments, brain abnormalities and eye movement change compared with first-episode schizophrenia (FSZ). These alterations may increase vulnerability to transitioning to the disease. This study explores cognitive-related functional connectivity (FC) and eye movement abnormalities to examine differences in the progression of schizophrenia.</p><p><strong>Methods: </strong>Thirty drug-naive FSZ, 28 CHR, and 30 healthy controls (HCs) were recruited to undergo resting-state functional magnetic resonance imaging (rs-fMRI). Connectome-based predictive modeling (CPM) was employed to extract cognitive-related brain regions, which were then selected as seeds to form FC networks. Support vector machine (SVM) was used to distinguish FSZ from CHR. Smooth pursuit eye-tracking tasks were conducted to assess eye movement features.</p><p><strong>Results: </strong>FSZ displayed decreased cognitive-related FC between right posterior cingulate cortex and right superior frontal gyrus compared with HCs and between right amygdala and left inferior parietal gyrus (IPG) compared with CHR. SVM analysis indicated a combination of BACS-SC and CFT-A scores, and FC between right amygdala and left IPG could serve as a potential biomarker for distinguishing FSZ from CHR with high sensitivity. FSZ also exhibited a wide range of eye movement abnormalities compared with HCs, which were associated with alterations in cognitive-related FC.</p><p><strong>Conclusions: </strong>FSZ and CHR exhibited different patterns of cognitive-related FC and eye movement alteration. Our findings illustrate potential neuroimaging and cognitive markers for early identification of psychosis that could help in the intervention of schizophrenia in high-risk groups.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"308"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of combined art-based intervention on functional connectivity of multiple brain networks in older adults along the cognitive continuum: result from a parallel randomised controlled trial.","authors":"Yuan-Jiao Yan, Rong Lin, Yu-Ting Luo, Chen-Shan Huang, Wen-Chao Cai, Jia-Wei Su, Sheng-Mei Lin, Mo-Jun Lin, Hong Li","doi":"10.1186/s12888-025-06741-3","DOIUrl":"10.1186/s12888-025-06741-3","url":null,"abstract":"<p><strong>Background: </strong>Combined art-based interventions (CAIs) are considered effective treatment options for older adults along the cognitive continuum; however, the neural mechanisms underlying associated changes in neurocognitive performance remain unclear. Thus, we aimed to investigate the impact of a CAI programme in older adults along the cognitive continuum and to understand its mechanism.</p><p><strong>Methods: </strong>This parallel-arm randomised controlled trial was conducted between April 2021 and January 2023. Participants were randomised in a 1:1 ratio to either intervention group (IG) or waitlist control group (WG). The IG underwent a 16-week CAI programme. Neuropsychological assessments and magnetic resonance imaging were conducted before and after the intervention.</p><p><strong>Results: </strong>After the intervention, the IG showed greater improvement in general cognitive function, language, and memory than the WG. Significant differences were observed in the functional connectivity (FC) values in the temporal and cerebellar anterior lobes, fusiform, inferior occipital, and lingual gyri, and perirhinal and visual cortices between the groups. Further analyses showed that FC values were reduced in these regions in the IG. In addition, changes in FC values were positively correlated with those in neuropsychological test scores in the IG.</p><p><strong>Conclusions: </strong>Our study suggests that the CAI programme can effectively improve general cognitive function, language, and memory in older adults along the cognitive continuum. These improvements may be changed due to decreases in FC in key brain regions, deepening the understanding of the neurocentral mechanisms that act as a tool for improving cognitive function.</p><p><strong>Trial registration: </strong>This trial was registered at ChiCTR.org. Identifier: ChiCTR2100044959, 03/04/2021.</p>","PeriodicalId":9029,"journal":{"name":"BMC Psychiatry","volume":"25 1","pages":"307"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}